Hancock Whitney Corp lowered its position in Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 10.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 4,526 shares of the biotechnology company’s stock after selling 526 shares during the period. Hancock Whitney Corp’s holdings in Blueprint Medicines were worth $485,000 at the end of […]
Analysts expect Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) to post $40.22 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Blueprint Medicines’ earnings, with the highest sales estimate coming in at $53.00 million and the lowest estimate coming in at $30.90 million. Blueprint Medicines […]
Exchange Traded Concepts LLC increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 51.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 661 shares of the biotechnology company’s stock after acquiring an additional 225 shares during […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) insider Ariel Hurley sold 2,339 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, March 10th. The stock was sold at an average price of $57.15, for a total value of $133,673.85. The transaction was disclosed in a document filed with the SEC, which is […]